Inhibrx, Inc. Common Stock
INBX
INBX was delisted on the 29th of May, 2024.
116 hedge funds and large institutions have $886M invested in Inhibrx, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 50 increasing their positions, 31 reducing their positions, and 10 closing their positions.
140% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 10
73% more capital invested
Capital invested by funds: $512M → $886M (+$374M)
61% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 31
14% more funds holding
Funds holding: 102 → 116 (+14)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
79% less call options, than puts
Call options by funds: $680K | Put options by funds: $3.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$113M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$39.2M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$19.4M |
| 4 |
State Street
Boston,
Massachusetts
|
+$13.7M |
| 5 |
PA
Perceptive Advisors
New York
|
+$12.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tybourne Capital Management
Hong Kong
|
-$16.2M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$5.87M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$5.25M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.29M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$2.94M |
INBX Hedge Fund Activity: Q4 2022 in Review
116 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Inhibrx, Inc. Common Stock (INBX) for Q4 2022, worth a combined $886M — up 73% from $512M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new INBX positions and 10 closed out — a net gain of 14 holders — while 50 added to existing stakes and 31 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $113M. The largest seller was Tybourne Capital Management, cutting an estimated $16.2M.
- 116 institutional investors held Inhibrx, Inc. Common Stock (INBX) as of Q4 2022, up from 102 in Q3 2022.
- Funds reported $886M of Inhibrx, Inc. Common Stock stock for Q4 2022, up 73% quarter-over-quarter.
- 24 funds opened new Inhibrx, Inc. Common Stock positions in Q4 2022 and 10 closed out, a net change of +14 holders.
- The largest Inhibrx, Inc. Common Stock buyer in Q4 2022 was RA Capital Management, an estimated $113M added.
- The largest Inhibrx, Inc. Common Stock seller in Q4 2022 was Tybourne Capital Management, an estimated $16.2M sold.
Based on aggregated 13F filings for Q4 2022.